Uterine fibroids and adenomyosis are common gynecological conditions that affect many women. While each of these conditions can present unique challenges, they share similarities in their impact on the uterus and reproductive health. One important factor in the development of both uterine fibroids and adenomyosis is genetics. Understanding the role of genetic factors can provide valuable insight into the causes of these conditions, as well as help guide treatment decisions for women living with them.
What Are Uterine Fibroids and Adenomyosis?
Before we get into the genetic factors, it’s important to briefly review the characteristics of these two conditions:
- Uterine Fibroids: These are non-cancerous tumors that grow in the walls of the uterus. They can vary in size and number and may cause symptoms such as heavy menstrual bleeding, pelvic pain, frequent urination, and pain during intercourse. Although fibroids are typically asymptomatic, they can cause significant discomfort for some women and may affect fertility.
- Adenomyosis: This condition occurs when endometrial tissue, which normally lines the inside of the uterus, grows into the muscular wall of the uterus. Adenomyosis often causes chronic pelvic pain, heavy menstrual bleeding, and painful periods. Unlike fibroids, which are distinct, well-defined growths, adenomyosis may be spread throughout the uterine muscle (diffuse) or concentrated in one area (focal).
Both conditions are common, and while the exact causes remain unclear, genetics is believed to play a key role in their development.
Genetic Factors in Uterine Fibroids
Research has shown that genetic factors are strongly associated with the development of uterine fibroids. Studies of families and twins suggest that fibroids tend to run in families, indicating a genetic predisposition.
Hereditary Factors
Women who have close relatives—such as a mother or sister—who have had fibroids are at a higher risk of developing them themselves, suggesting that hereditary factors contribute to their formation. In rare families, fibroids that appear at a young age are part of an inherited syndrome caused by mutations in the FH gene (hereditary leiomyomatosis and renal cell cancer), which also raises the risk of kidney cancer and calls for genetic counseling.
Inherited gene variants may also be involved. Large genome-wide studies have linked dozens of common genetic variants to fibroid risk, each adding a small amount of risk. Fibroids are also hormone-sensitive, relying on estrogen and progesterone to grow, and genetics may influence how fibroid tissue responds to these hormones.
Genetic Factors
Fibroids are associated with genetic changes in the uterine muscle cells. Many fibroids carry specific mutations that are absent in normal uterine tissue. The most common involves the MED12 gene, a regulator of gene activity that is altered in about 70% of fibroids; others involve genes such as HMGA2 or FH. These changes can make cells grow abnormally, leading to the formation of fibroids.
In addition, fibroids may contain altered genes that affect cellular growth regulation, apoptosis (programmed cell death), and vascularization (blood vessel formation), all of which contribute to fibroid development. These findings suggest that uterine fibroids may have a strong genetic basis in their development and growth.
Genetic Factors in Adenomyosis
While adenomyosis is less well understood than fibroids, genetic factors are also thought to play a role in its development. Some evidence suggests that adenomyosis may cluster in families, although this has been studied far less than in fibroids.
Genetic Links and Family History
Some research suggests that adenomyosis may run in families, but the evidence is limited and the specific inherited genes involved remain unclear. Studies of adenomyosis tissue have found acquired mutations, such as in the KRAS gene, within the affected cells.
Unlike fibroids, where chromosomal abnormalities have been well-documented, the genetic factors contributing to adenomyosis are still being explored. Some studies suggest that inflammation and hormonal imbalances—particularly an imbalance between estrogen and progesterone—may play a role in the development of adenomyosis. The hormonal influences on adenomyosis could be genetically determined, meaning that women with certain genetic profiles might be more likely to develop adenomyosis in response to hormonal fluctuations, especially after childbirth.
Environmental and Hormonal Interactions
While genetic predisposition plays a role, other factors also influence the development of adenomyosis. For instance, women who have had multiple pregnancies or prior uterine procedures, such as cesarean delivery or dilation and curettage, are more likely to develop the condition. These factors may interact with genetic susceptibility, potentially promoting the growth of endometrial tissue into the muscular wall of the uterus.
Hormonal influences, especially exposure to estrogen during the reproductive years, can stimulate the growth of endometrial tissue. If a woman has a genetic susceptibility to adenomyosis, the hormonal changes associated with menstruation, pregnancy, and childbirth could contribute to the condition.
How Genetic Factors Influence Treatment
Research into the genetic components of uterine fibroids and adenomyosis is improving our understanding of these conditions, although genetic testing is not currently part of routine diagnosis or treatment planning.
Personalized Treatment Plans
Today, treatment is tailored to your symptoms, the size and location of fibroids or adenomyosis, and your reproductive goals rather than to genetic test results. For example, women with fibroids may benefit from hormonal therapies, such as birth control pills, hormonal IUDs, or GnRH-based medications, which can help control bleeding and alleviate symptoms. Response to these treatments varies from woman to woman, and researchers are studying whether genetic differences help explain why.
Targeted Therapies
As research into the genetic underpinnings of these conditions advances, targeted therapies that address specific genetic mutations may become available in the future. For example, medications that target specific genes involved in fibroid growth may offer more effective and personalized treatment options, reducing the need for invasive procedures like surgery.
Coping with the Emotional Impact of Genetic Factors
Understanding that genetics play a role in the development of uterine fibroids and adenomyosis can be both enlightening and emotional. It’s common for women to feel frustrated or helpless when faced with a family history of these conditions, especially if they’ve experienced the physical, emotional, and social challenges associated with them.
If you’re dealing with either of these conditions, it’s important to acknowledge and process your feelings. You are not alone in this journey. Many women find strength in connecting with others who understand their experiences. Support groups and counseling can offer a compassionate outlet for addressing the emotional impact of living with fibroids or adenomyosis, while helping you stay informed and empowered.
Support for Fibroids and Adenomyosis in New York at 1Fibroid
While genetic predisposition doesn’t determine your destiny, it is an important part of the puzzle. With the right knowledge, medical care, and emotional support, women can manage the symptoms of fibroids and adenomyosis and improve their quality of life. If you are struggling with these conditions, know that compassionate care is available, and personalized treatments can offer relief and support for your health journey.
For women struggling with symptoms of fibroids or adenomyosis, 1Fibroid in New York is here to support you so you can help you regain control over your health and improve your overall quality of life. Call 212-991-9991 today to learn more about UFE, UAE, and other options, and ask how we can support you on your journey to better health and symptom relief.
Sources
- Guideline No. 437: Diagnosis and Management of Adenomyosis. Society of Obstetricians and Gynaecologists of Canada / J Obstet Gynaecol Can, 2023.
- MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science, 2011.
- Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci U S A, 2016.
- Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. Nat Commun, 2019.
- Heritability and risk factors of uterine fibroids--the Finnish Twin Cohort study. Maturitas, 2000.
- FH Tumor Predisposition Syndrome. GeneReviews (NCBI Bookshelf).
- Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun, 2019.
- Adenomyosis: Diagnosis and Management. Am Fam Physician, 2022.